Finanzen von Cytosorbents Corp (CTSO)CTSOCytosorbents Corp

Cytosorbents Corp (CTSO) generates its revenue primarily from CytoSorb and other sales, which accounts for 100.0% of total sales, equivalent to $9.48M. Understanding this concentration is critical for investors evaluating how CTSO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Cytosorbents Corp maintains a gross margin of 73.18%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -24.58%, while the net margin is -45.85%. These profitability ratios, combined with a Return on Equity (ROE) of -336.21%, provide a clear picture of how effectively CTSO converts its operational activities into shareholder value.

In the context of the broader market, CTSO competes directly with industry leaders such as CTXR and MDXH. With a market capitalization of $15.10M, it holds a significant position in the sector. When comparing efficiency, CTSO's gross margin of 73.18% stands against CTXR's 67.07% and MDXH's N/A. Such benchmarking helps identify whether Cytosorbents Corp is trading at a premium or discount relative to its financial performance.

Cytosorbents has shown fluctuating revenue, with Q2 2026 revenue at $9.63 million, but has consistently reported net losses, including a net income of -$4.42 million in Q2 2026. The gross margin is relatively high at 73.18%, indicating good product profitability despite overall losses.